Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
GEGP-WILL-BE-RUNNING-SOON. JMHO
YOU GUYS DO A GREAT JOB HERE. $$$$$$$$$$
AGAIN THE DOTS ARE CONNECTED FOR FDFT
RDHL-$11.30-COVID-PILL-SHOWING-GOOD-FOR-ANY-STRAIN-STORY-BELOW-And indeed, the benefits of this approach are now becoming even more apparent. The target that we’re looking at isn’t affected by mutations of the spike protein on the virus.
The different mutations affect the virus that may overcome direct antibodies targeting the spike, but we are going further downstream to inhibit viral replication. It is thus not affected by the mutation. Opaganib’s potential to be active against all the different SARS-CoV-2 variants could be a distinguishing factor.
And another important distinguishing factor is the fact opaganib is oral. It’s easy to distribute and administer it. We can foresee its use in outpatient settings in mild cases of COVID-19 in the future and the more severe hospitalized cases. IV products are much harder to administer and distribute to patients outside of hospitals.
RDHL-$11.30-COVID-PILL-SHOWING-GOOD-FOR-ANY-STRAIN-STORY-BELOW-And indeed, the benefits of this approach are now becoming even more apparent. The target that we’re looking at isn’t affected by mutations of the spike protein on the virus.
The different mutations affect the virus that may overcome direct antibodies targeting the spike, but we are going further downstream to inhibit viral replication. It is thus not affected by the mutation. Opaganib’s potential to be active against all the different SARS-CoV-2 variants could be a distinguishing factor.
And another important distinguishing factor is the fact opaganib is oral. It’s easy to distribute and administer it. We can foresee its use in outpatient settings in mild cases of COVID-19 in the future and the more severe hospitalized cases. IV products are much harder to administer and distribute to patients outside of hospitals.
RDHL-11.30-COVID-PILL-SHOWING-GOOD-FOR-ANY-STRAIN-STORY-HERE-And indeed, the benefits of this approach are now becoming even more apparent. The target that we’re looking at isn’t affected by mutations of the spike protein on the virus.
The different mutations affect the virus that may overcome direct antibodies targeting the spike, but we are going further downstream to inhibit viral replication. It is thus not affected by the mutation. Opaganib’s potential to be active against all the different SARS-CoV-2 variants could be a distinguishing factor.
And another important distinguishing factor is the fact opaganib is oral. It’s easy to distribute and administer it. We can foresee its use in outpatient settings in mild cases of COVID-19 in the future and the more severe hospitalized cases. IV products are much harder to administer and distribute to patients outside of hospitals.
TODAY I CUT AND PASTED PART OF THE STORY YOU POSTED ON BB STOCK HAVEN, MOMO'S STOCK BOARD AND OTHER BOARDS WHERE YOU CAN POST DIFFERENT STOCKS. PEOPLE HERE SHOULD BE SPREADING THE WORD FROM THAT STORY ALL OVER. I DON'T TWEET BUT IF PEOPLE HERE DO THEY SHOULD PASTE IT AND GET IT OUT THERE. EVEN FACEBOOK. IF ANY OF YOU GUYS DO FACEBOOK TRY AND SPREAD THE WORD. GLTA LONGS
RDHL-$11.00-COVID-MEDS-STORY-GOOD-FOR-ALL-STRAINS-And indeed, the benefits of this approach are now becoming even more apparent. The target that we’re looking at isn’t affected by mutations of the spike protein on the virus.
The different mutations affect the virus that may overcome direct antibodies targeting the spike, but we are going further downstream to inhibit viral replication. It is thus not affected by the mutation. Opaganib’s potential to be active against all the different SARS-CoV-2 variants could be a distinguishing factor.
And another important distinguishing factor is the fact opaganib is oral. It’s easy to distribute and administer it. We can foresee its use in outpatient settings in mild cases of COVID-19 in the future and the more severe hospitalized cases. IV products are much harder to administer and distribute to patients outside of hospitals.
RDHL-$11.00-COVID-MED-STORY--THE-NEXT-NVAX-And indeed, the benefits of this approach are now becoming even more apparent. The target that we’re looking at isn’t affected by mutations of the spike protein on the virus.
The different mutations affect the virus that may overcome direct antibodies targeting the spike, but we are going further downstream to inhibit viral replication. It is thus not affected by the mutation. Opaganib’s potential to be active against all the different SARS-CoV-2 variants could be a distinguishing factor.
And another important distinguishing factor is the fact opaganib is oral. It’s easy to distribute and administer it. We can foresee its use in outpatient settings in mild cases of COVID-19 in the future and the more severe hospitalized cases. IV products are much harder to administer and distribute to patients outside of hospitals.
RDHL-$11.00-COVID-MEDS-GOOD-FOR-ALL-STRAINS-NEWS-STORY-And indeed, the benefits of this approach are now becoming even more apparent. The target that we’re looking at isn’t affected by mutations of the spike protein on the virus.
The different mutations affect the virus that may overcome direct antibodies targeting the spike, but we are going further downstream to inhibit viral replication. It is thus not affected by the mutation. Opaganib’s potential to be active against all the different SARS-CoV-2 variants could be a distinguishing factor.
And another important distinguishing factor is the fact opaganib is oral. It’s easy to distribute and administer it. We can foresee its use in outpatient settings in mild cases of COVID-19 in the future and the more severe hospitalized cases. IV products are much harder to administer and distribute to patients outside of hospitals.
RDHL-11.00=NEW-COVID-TREATMENT-FOR-EVERY-STRAINS-NEWS-STORY-And indeed, the benefits of this approach are now becoming even more apparent. The target that we’re looking at isn’t affected by mutations of the spike protein on the virus.
The different mutations affect the virus that may overcome direct antibodies targeting the spike, but we are going further downstream to inhibit viral replication. It is thus not affected by the mutation. Opaganib’s potential to be active against all the different SARS-CoV-2 variants could be a distinguishing factor.
And another important distinguishing factor is the fact opaganib is oral. It’s easy to distribute and administer it. We can foresee its use in outpatient settings in mild cases of COVID-19 in the future and the more severe hospitalized cases. IV products are much harder to administer and distribute to patients outside of hospitals.
RDHL-COVID-MED-STORY-AND-EXPLANATION- And indeed, the benefits of this approach are now becoming even more apparent. The target that we’re looking at isn’t affected by mutations of the spike protein on the virus.
The different mutations affect the virus that may overcome direct antibodies targeting the spike, but we are going further downstream to inhibit viral replication. It is thus not affected by the mutation. Opaganib’s potential to be active against all the different SARS-CoV-2 variants could be a distinguishing factor.
And another important distinguishing factor is the fact opaganib is oral. It’s easy to distribute and administer it. We can foresee its use in outpatient settings in mild cases of COVID-19 in the future and the more severe hospitalized cases. IV products are much harder to administer and distribute to patients outside of hospitals.
FDFT IS A MONEY MACHINE AND A GOLD MINE WAITING TO HAPPEN
$17 MILLION IN REVS AND SELLING FOR .0009. IS AMAZING.
DD SHOWS 17 MILLION IN REVENUE
THANKS FOR YOUR OPINION. NOW WHY DON'T YOU FIND A PINKY THAT YOU BELIEVE IN
AND HOW DO YOU KNOW THIS? I SAY IT DOES
WE NOW-KNOW-THIS-WILL-BE-GOOD-FOR-ANY-STRAIN-OF-COVID!
POS-WITH-NOTHING-BUT-A-DREAM-RUN-WILD.-THIS-IS-A-REAL-COMPANY.
FOR-A-COMPANY-WITH-17MILLION-IN-REVS-THIS-IS-DIRT-CHEAP. $$$$$$$$$$$$$$
ONE-WOULD-THINK-OLD-WEBSITE-GONE-MEANS-NEW-ONE-COMES. JMHO
17-MILLION-IREVS-NEW-PLANT-BASED-MEAT-COMPANY-ADDING-ON-$$$$$$$$
R/M WITH PLANT-BASED-MEAT-COMPANY
INCHING-UP-EVERY-DAY-BREAKOUT-SOON?
OLD WEBSITE GONE NEW ONE COMING
FDFT-.0015-ASK-.0019-GAPPER-RUN-INTO-20"S-TODAY
FDFT-.0015-ASK-.0019-GAPPER-BREAK-THRU-20'S TODAY
FDFT-.0015-ASK-.0019-GAPPER-RUN-THRU-20'S-TODAY
WE-PUSH-INTO-THE-20'S-TODAY!
ONE-DAY-SOON-THIS-WILL-JUST-FLY.
1 TREQATMENT FOR HOME CARE COVID. ONE FOR SERIOUSLY ILL COVID
2-COVID-TREATMENTS-FOR COVID-PHASE-2/3-TRIALS
thanks-great-news-2-treatments-from one company.
GREAT TWEET OUT. THANKS FOR THE POST.
ONE OF THESE-DAYS-IT-WILL-PUSH-RIGHT-THRU-.0020
20'S TOMORROW.
HIGHER VOLUME-ON THE UP SIDE GOING-UP.
rdhl-10.80-up-1.10-med-for-covid-proven-to-work.
mikp-.0009-up-.0003-ceo-to-bring-company-from-expert-to-pink
MIKP-.0009-YES-breakout-here-looking-good-going-to-pink-from-expert